The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Comprehensive molecular portraits of human breast tumours
Open accessAbstract
We analysed primary breast cancers by genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and reverse-phase protein arrays. Our ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers; however, there were numerous subtype-associated and novel gene mutations including the enrichment of specific mutations in GATA3, PIK3CA and MAP3K1 with the luminal A subtype. We identified two novel protein-expression-defined subgroups, possibly produced by stromal/microenvironmental elements, and integrated analyses identified specific signalling pathways dominant in each molecular subtype including a HER2/phosphorylated HER2/EGFR/phosphorylated EGFR signature within the HER2-enriched expression subtype. Comparison of basal-like breast tumours with high-grade serous ovarian tumours showed many molecular commonalities, indicating a related aetiology and similar therapeutic opportunities. The biological finding of the four main breast cancer subtypes caused by different subsets of genetic and epigenetic abnormalities raises the hypothesis that much of the clinically observable plasticity and heterogeneity occurs within, and not across, these major biological subtypes of breast cancer. The Cancer Genome Atlas Network describe their multifaceted analyses of primary breast cancers, shedding light on breast cancer heterogeneity; although only three genes (TP53, PIK3CA and GATA3) are mutated at a frequency greater than 10% across all breast cancers, numerous subtype-associated and novel mutations were identified. This Article from the Cancer Genome Atlas consortium describes a multifaceted analysis of primary breast cancers in 825 people. Exome sequencing, copy number variation, DNA methylation, messenger RNA arrays, microRNA sequencing and proteomic analyses were performed and integrated to shed light on breast-cancer heterogeneity. Just three genes — TP53, PIK3CA and GATA3 — are mutated at greater than 10% frequency across all breast cancers. Many subtype-associated and novel mutations were identified, as well as two breast-cancer subgroups with specific signalling-pathway signatures. The analyses also suggest that much of the clinically observable plasticity and heterogeneity occurs within, and not across, the major subtypes of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In breast cancer, hypoxia is more evident in TNBC than in other breast cancer subtypes11,12.”
From Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoxia-inducible factor 1α (HIF-1α) is a master transcription factor that is highly expressed in cancer tissues, including breast cancer, and is particularly enriched in triple-negative breast cancer (TNBC)2.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“A recent analysis, combining mutation, mRNA expression and protein levels, determined that the PI3K/Akt pathway was elevated in basal-like cancers as compared with luminal or HER2+ (47).”
From Mislocalization of the Cell Polarity Protein Scribble Promotes Mammary Tumorigenesis and Is Associated with Basal Breast Cancer (2014) · cites this paper as [47]
In the citing paper
“data analysis of The Cancer Genome Atlas (TCGA) dataset11 identified that hypoxic gene signature, which includes commonly documented hypoxia-responsive genes26, was inversely correlated with immune effector genes (IFNG, TNF, GZMB, PRF1), IFNγ-responsive genes, as well as genes associated with tumor-infiltrating lymphocytes (TILs) in TNBC (n = 99) (also referred as a basal subtype of breast cancer)”
In the citing paper
“Kaplan–Meier analysis using public breast cancer meta-analysis database11,30 reveals that TNBC patients with higher hypoxia gene signature are associated with worse disease outcomes, including both overall survival (OS) and distant metastasis-free survival (DMFS), compared to those with lower expression of hypoxia gene signature (Fig. 1h).”
In the citing paper
“Analysis of hundreds of triple-negative breast cancers revealed a wide diversity of somatic mutations none of which were found at high frequency [4].”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [4]
In the citing paper
“Given the remarkable overexpression of HIF target genes in triple-negative breast cancer [4, 21], the master regulatory role of HIFs in metastasis (Fig. 5), and their involvement in chemotherapy resistance, HIF inhibitors may represent a targeted therapy for these breast cancers.”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Self-citationA Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J. B., Cronin, M. T., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,321
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R. J., Parker, J. S., Hastie, T. J., Marron, J. S., Nobel, A. B., Deng, S., Johnsen, H., Pesich, R., Geisler, S. B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,508
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,818
Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases
Johnson, G. L., & Lapadat, R. (2002) · Science · doi:10.1126/science.1072682 · Cited by 4,295
Cited by
Sorted by citations
Items 601–700 of 1,085
Xu, G., Chhangawala, S., Cocco, E., Razavi, P., Cai, Y., Otto, J. E., Ferrando, L., Selenica, P., Ladewig, E., Chan, C., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0554-0 · Cited by 234
PI3K/Akt/mTOR inhibitors in breast cancer.
Lee, J. J. X., Loh, K. W.-J., & Yap, Y. S. (2015) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2015.0089 · Cited by 230
Breast cancer quantitative proteome and proteogenomic landscape
Johansson, H. J., Socciarelli, F., Vacanti, N. M., Haugen, M. H., Zhu, Y., Siavelis, I., Fernandez-Woodbridge, A., Aure, M. R. R., Sennblad, B., Vesterlund, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09018-y · Cited by 233
Clinical utility of gene-expression signatures in early stage breast cancer
Kwa, M. J., Makris, A., & Esteva, F. J. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.74 · Cited by 233
PanCancer insights from The Cancer Genome Atlas: the pathologist's perspective
Cooper, L., Demicco, E. G., Saltz, J. H., Powell, R. T., Rao, A. U. K., & Lazar, A. J. (2017) · The Journal of Pathology · doi:10.1002/path.5028 · Cited by 237
Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
Chandarlapaty, S., Sakr, R. A., Giri, D. D., Patil, S. N., Heguy, A., Morrow, M., Modi, S., Norton, L., Rosen, N. X., Hudis, C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1785 · Cited by 228
Prat, A., Bianchini, G., Thomas, M., Belousov, A., Cheang, M. C. U., Koehler, A., Gómez, P., Семиглазов, В. Ф., EIERMANN, W., Tjulandin, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0239 · Cited by 235
Kinetic competition during the transcription cycle results in stochastic RNA processing
Coulon, A., Ferguson, M., de Turris, V., Palangat, M., Chow, C. C., & Larson, D. R. (2014) · eLife · doi:10.7554/elife.03939 · Cited by 229
Nayar, U., Cohen, O., Kapstad, C., Cuoco, M. S., Waks, A. G., Wander, S. A., Painter, C., Freeman, S. S., Persky, N. S., Marini, L., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0287-5 · Cited by 232
TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines
Shahbandi, A., Nguyen, H. D., & Jackson, J. G. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.007 · Cited by 241
Rahmioglu, N., Fassbender, A., Vitonis, A. F., Tworoger, S. S., Hummelshoj, L., D'Hooghe, T. M., Adamson, G. D., Giudice, L. C., Becker, C. M., Zondervan, K. T., et al. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.07.1208 · Cited by 227
The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap
Ellis, M. J., & Perou, C. M. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0462 · Cited by 231
Stover, D. G., Parsons, H. A., Ha, G., Freeman, S. S., Barry, W. T., Guo, H., Choudhury, A. D., Gydush, G., Reed, S. C., Rhoades, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0033 · Cited by 230
Hurvitz, S. A., Martín, M., Press, M. F., Chan, D., Fernández-Abad, M., Petru, E., Rostorfer, R., Guarneri, V., Huang, C., Barriga, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1425 · Cited by 229
Chaturvedi, P., Gilkes, D. M., Takano, N., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406655111 · Cited by 226
Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway
Hassan, B., Akçakanat, A., Holder, A. M., & Meric‐Bernstam, F. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.008 · Cited by 230
Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER
van den Beucken, T., Koch, E., Chu, K., Rupaimoole, R., Prickaerts, P., Adriaens, M. E., Voncken, J. W., Harris, A. L., Buffa, F. M., Haider, S. A., et al. (2014) · Nature Communications · doi:10.1038/ncomms6203 · Cited by 229
MYC-Driven Pathways in Breast Cancer Subtypes
Fallah, Y., Brundage, J., Allegakoen, P., & Shajahan‐Haq, A. N. (2017) · Biomolecules · doi:10.3390/biom7030053 · Cited by 226
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments
Testa, U., Castelli, G., & Pelosi, E. (2020) · Medical Sciences · doi:10.3390/medsci8010018 · Cited by 238
DeepCC: a novel deep learning-based framework for cancer molecular subtype classification
Gao, F., Wang, W., Tan, M., Zhu, L., Zhang, Y., Fessler, E., Vermeulen, L., & Wang, X. (2019) · Oncogenesis · doi:10.1038/s41389-019-0157-8 · Cited by 226
Genome-driven integrated classification of breast cancer validated in over 7,500 samples
Ali, H. R., Rueda, O. M., Chin, S., Curtis, C. N., Dunning, M., Aparicio, S. A. J. R., & Caldas, C. (2014) · Genome biology · doi:10.1186/s13059-014-0431-1 · Cited by 229
SOX4: The unappreciated oncogene
Moreno, C. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.027 · Cited by 227
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
Eikesdal, H. P., Yndestad, S., Elzawahry, A., Llop‐Guevara, A., Gilje, B., Blix, E. S., Espelid, H., Lundgren, S., Geisler, J., Vagstad, G., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.009 · Cited by 228
Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer
White, N. M. A., Cabanski, C. R., Silva-Fisher, J., Dang, H. X., Govindan, R., & Maher, C. A. (2014) · Genome biology · doi:10.1186/preaccept-8565849481270705 · Cited by 225
Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials
Maennling, A. E., Tur, M. K., Niebert, M., Klockenbring, T., Zeppernick, F. A., Gattenlöhner, S., Meinhold-Heerlein, I. M., & Hussain, A. F. (2019) · Cancers · doi:10.3390/cancers11121826 · Cited by 226
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer
Bowling, E. A., Wang, J. H., Gong, F., Wu, W., Neill, N. J., Kim, I. S., Tyagi, S., Orellana, M. C., Kurley, S. J., Domínguez-Vidaña, R., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.031 · Cited by 227
Genetic Susceptibility to Triple-Negative Breast Cancer
Purrington, K. S., Vachon, C. M., & Couch, F. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1699 · Cited by 229
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance
Katzenellenbogen, J. A., Mayne, C. G., Katzenellenbogen, B. S., Greene, G. L., & Chandarlapaty, S. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0001-z · Cited by 225
Efficacy of PI3K inhibitors in advanced breast cancer
Verret, B., Cortes, J., Bachelot, T., Andre, F., & Arnedos, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz381 · Cited by 221
A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer
Peng, X., Xu, X., Wang, Y., Hawke, D. H., Yu, S., Han, L., Zhou, Z., Mojumdar, K., Jeong, K. J., Labrie, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.026 · Cited by 227
Siddharth, S., & Sharma, D. (2018) · Cancers · doi:10.3390/cancers10120514 · Cited by 221
Barèche, Y., Buisseret, L., Gruosso, T., Girard, E., Venet, D., Dupont, F., Desmedt, C., Larsimont, D., Park, M., Rothé, F., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz208 · Cited by 221
Benchmarking joint multi-omics dimensionality reduction approaches for the study of cancer
Cantini, L., Zakeri, P., Hernandez, C., Naldi, A., Thieffry, D., Rémy, É., & Baudot, A. (2021) · Nature Communications · doi:10.1038/s41467-020-20430-7 · Cited by 239
Asleh, K., Riaz, N., & Nielsen, T. O. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02476-1 · Cited by 235
Craig, D. W., O'Shaughnessy, J. A., Kiefer, J. A., Aldrich, J., Sinari, S., Moses, T. M., Wong, S., Dinh, J., Christoforides, A., Blum, J. L., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0781 · Cited by 220
Master regulators of FGFR2 signalling and breast cancer risk
Fletcher, M. N. C., Castro, M. A. A., Wang, X., de Santiago, I., O’Reilly, M., Chin, S., Rueda, O. M., Caldas, C., Ponder, B. A. J., Markowetz, F. M., et al. (2013) · Nature Communications · doi:10.1038/ncomms3464 · Cited by 226
PI3K/Akt-mediated regulation of p53 in cancer
Abraham, A., & O’Neill, E. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140070 · Cited by 225
Matulonis, U. A., Wulf, G. M., Barry, W. T., Birrer, M. J., Westin, S. N., Farooq, S., Bell-McGuinn, K. M., Obermayer, E., Whalen, C., Spagnoletti, T., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw672 · Cited by 220
PI3K Inhibitors in Breast Cancer Therapy
Ellis, H., & Ma, C. X. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0846-7 · Cited by 226
Cyclin D-CDK4/6 functions in cancer
Gao, X., Leone, G. W., & Wang, H. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.02.002 · Cited by 226
Genomic landscapes of breast fibroepithelial tumors
Tan, J. Y., Ong, C. K., Lim, W. K., Ng, C. C. Y., Thike, A. A., Ng, L. M., Rajasegaran, V., Myint, S. S., Nagarajan, S., Thangaraju, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3409 · Cited by 219
The Proteomic Landscape of Triple-Negative Breast Cancer
Lawrence, R., Perez, E. M., Hernández, D., Miller, C. P., Haas, K. M., Irie, H. Y., Lee, S., Blau, C. A., & Villén, J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.050 · Cited by 225
Piperine inhibits the growth and motility of triple-negative breast cancer cells
Greenshields, A. L., Doucette, C. D., Sutton, K. M., Madera, L., Annan, H. G., Yaffe, P. B., Knickle, A. F., Dong, Z., & Hoskin, D. W. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.017 · Cited by 219
Aromatase expression and regulation in breast and endometrial cancer
Zhao, H., Zhou, L., Shangguan, A. J., & Bulun, S. E. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0310 · Cited by 222
Clinical significance of the integrin α6β4 in human malignancies
Stewart, R. L., & O’Connor, K. L. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2015.82 · Cited by 219
Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
Rani, A., Stebbing, J., Giamas, G., & Murphy, J. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00245 · Cited by 224
The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes
Onkar, S., Carleton, N. M., Lucas, P. C., Bruno, T. C., Lee, A. V., Vignali, D. A. A., & Oesterreich, S. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0475 · Cited by 227
mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo
Rybakova, Y., Kowalski, P. S., Huang, Y., Gonzalez, J. T., Heartlein, M. W., DeRosa, F., Delcassian, D., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.012 · Cited by 218
Hsp90, an unlikely ally in the war on cancer
Barrott, J. J., & Haystead, T. (2013) · FEBS Journal · doi:10.1111/febs.12147 · Cited by 225
Raphael, B. J., Dobson, J. R., Oesper, L., & Vandin, F. (2014) · Genome Medicine · doi:10.1186/gm524 · Cited by 226
Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer
Drake, J. M., Paull, E., Graham, N. A., Lee, J. K., Smith, B. A., Titz, B., Stoyanova, T. I., Faltermeier, C. M., Uzunangelov, V., Carlin, D. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.007 · Cited by 223
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer
Nunnery, S. E., & Mayer, I. A. (2020) · Drugs · doi:10.1007/s40265-020-01394-w · Cited by 225
Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides
Huang, D., Zhu, X., Ye, S., Zhang, J., Liao, J., Zhang, N., Zeng, X., Wang, J., Yang, B., Zhang, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06834-7 · Cited by 222
Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism
Rižner, T. L., & Penning, T. M. (2014) · Steroids · doi:10.1016/j.steroids.2013.10.012 · Cited by 217
Telonis, A. G., Magee, R. G., Loher, P., Chervoneva, I., Londin, E. R., & Rigoutsos, I. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx082 · Cited by 219
Pfefferle, A. D., Herschkowitz, J. I., Usary, J., Harrell, J. C., Spike, B. T., Adams, J. R., Torres‐Arzayus, M. I., Brown, M. A., Egan, S. E., Wahl, G. M., et al. (2013) · Genome biology · doi:10.1186/gb-2013-14-11-r125 · Cited by 225
Integrative methods for analyzing big data in precision medicine
Gligorijević, V., Malod‐Dognin, N., & Pržulj, N. (2015) · PROTEOMICS · doi:10.1002/pmic.201500396 · Cited by 226
Fatty acid metabolism in breast cancer subtypes
Monaco, M. E. (2017) · Oncotarget · doi:10.18632/oncotarget.15494 · Cited by 216
Zhang, Y., Chen, F., Chandrashekar, D. S., Varambally, S., & Creighton, C. J. (2022) · Nature Communications · doi:10.1038/s41467-022-30342-3 · Cited by 231
A general approach for detecting expressed mutations in AML cells using single cell RNA-sequencing
Petti, A. A., Williams, S. R., Miller, C. A., Fiddes, I. T., Srivatsan, S. N., Chen, D. Y., Fronick, C. C., Fulton, R. S., Church, D. M., & Ley, T. J. (2019) · Nature Communications · doi:10.1038/s41467-019-11591-1 · Cited by 215
TCGA-assembler 2: software pipeline for retrieval and processing of TCGA/CPTAC data
Wei, L., Jin, Z., Yang, S., Xu, Y., Zhu, Y., & Ji, Y. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx812 · Cited by 215
PIK3CA in cancer: The past 30 years
Arafeh, R., & Samuels, Y. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.002 · Cited by 220
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?
Martorana, F., Motta, G., Pavone, G., Motta, L., Stella, S., Vitale, S. R., Manzella, L., & Vigneri, P. G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.662232 · Cited by 218
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation
Welte, T., Kim, I. S., Tian, L. H., Gao, X., Wang, H., Li, J., Holdman, X. B., Herschkowitz, J. I., Pond, A. C., Xie, G., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3355 · Cited by 217
Lambin, P., Roelofs, E., Reymen, B. J. T., Velazquez, E. R., Buijsen, J., Zegers, C. M. L., Carvalho, S., Leijenaar, R. T. H., Nalbantov, G. I., Oberije, C., et al. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.07.007 · Cited by 213
Pelicano, H., Zhang, W., Liu, J., Hammoudi, N., Dai, J., Xu, R., Pusztai, L., & Huang, P. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0434-6 · Cited by 221
NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis
Park, M. K., Zhang, L., Min, K., Cho, J.-H., Yeh, C., Moon, H., Hormaechea‐Agulla, D., Mun, H., Ko, S., Lee, J. W., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.11.011 · Cited by 216
Seminal plasma as a diagnostic fluid for male reproductive system disorders
Drabovich, A. P., Saraon, P., Jarvi, K. A., & Diamandis, E. P. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.74 · Cited by 221
Dalin, M. G., Desrichard, A., Katabi, N., Makarov, V., Walsh, L. A., Lee, K.-W., Wang, Q., Armenia, J., West, L., Doğan, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0637 · Cited by 212
Shiao, S. L., Gouin, K. H., Ing, N., Ho, A. Y., Basho, R. K., Shah, A. S., Mebane, R. H., Zitser, D., Martinez, A., Mevises, N.-Y., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.012 · Cited by 212
Improved breast cancer histological grading using deep learning
Wang, Y., Acs, B., Robertson, S., Liu, B., Solorzano, L., Wählby, C., Hartman, J., & Rantalainen, M. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.007 · Cited by 211
Tight junction proteins: From barrier to tumorigenesis
Runkle, E. A., & Mu, D. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.05.038 · Cited by 216
Drug resistance to targeted therapies: Déjà vu all over again
Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 222
Ki67 and proliferation in breast cancer
Pathmanathan, N., & Balleine, R. L. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201085 · Cited by 211
Metastatic progression of breast cancer: insights from 50 years of autopsies
Cummings, M. C., Simpson, P. T., Reid, L., Jayanthan, J., Skerman, J., Song, S., Reed, A. E. M., Kutasovic, J. R., Morey, A. L., Marquart, L., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4288 · Cited by 210
Gasparini, P., Lovat, F., Fassan, M., Casadei, L., Cascione, L., Jacob, N. K., Carasi, S., Palmieri, D., Costinean, S., Shapiro, C. L., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402604111 · Cited by 216
Tsimberidou, A. M., Wen, S., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S. A., Naing, A., Jankú, F., Aldape, K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0603 · Cited by 210
Papanicolaou, M., Parker, A. L., Yam, M., Filipe, E. C., Wu, S. Z., Chitty, J. L., Wyllie, K., Tran, E., Mok, E. T. Y., Nadalini, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32255-7 · Cited by 225
Zhang, H., Jiang, R., Zhu, J., Sun, K.-N., Huang, Y., Zhou, H., Zheng, Y., & Wang, X. (2024) · Breast Cancer · doi:10.1007/s12282-024-01567-5 · Cited by 210
Pan-Cancer Analyses Reveal Genomic Features of FOXM1 Overexpression in Cancer
Barger, C. J., Branick, C., Chee, L., & Karpf, A. R. (2019) · Cancers · doi:10.3390/cancers11020251 · Cited by 209
Tumour heterogeneity and the evolutionary trade-offs of cancer
Hausser, J., & Alon, U. S. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0241-6 · Cited by 216
JARID1B Is a Luminal Lineage-Driving Oncogene in Breast Cancer
Yamamoto, S., Wu, Z., Russnes, H. G., Takagi, S., Peluffo, G., Vaske, C. J., Zhao, X., Vollan, H. K. M., Maruyama, R., Ekram, M. B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.024 · Cited by 209
Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer
Jiang, G., Zhang, S., Yazdanparast, A., Li, M., Pawar, A., Liu, Y., Inavolu, S. M., & Cheng, L. (2016) · BMC Genomics · doi:10.1186/s12864-016-2911-z · Cited by 210
Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment
Laborda-Illanes, A., Sánchez‐Alcoholado, L., Domínguez-Recio, M. E., Jiménez-Rodríguez, B., Lavado-Valenzuela, R., Comino‐Méndez, I., Alba, E., & Queipo‐Ortuño, M. I. (2020) · Cancers · doi:10.3390/cancers12092465 · Cited by 214
Chakrabarti, R., Wei, Y., Hwang, J., Hang, X., Blanco, M. A., Choudhury, A., Tiede, B., Romano, R. A., DeCoste, C. J., Mercatali, L., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3040 · Cited by 215
Evolutionary foundations for cancer biology
Aktipis, A., & Nesse, R. M. (2013) · Evolutionary Applications · doi:10.1111/eva.12034 · Cited by 207
Pareja, F. G., Geyer, F. C., Marchiò, C., Burke, K. A., Weigelt, B., & Reis-Filho, J. S. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2016.36 · Cited by 214
Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib
Kwapisz, D. M. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4385-3 · Cited by 210
Noorbakhsh, J., Farahmand, S., Foroughi pour, A., Namburi, S., Caruana, D., Rimm, D., Soltanieh-ha, M., Zarringhalam, K., & Chuang, J. H. (2020) · Nature Communications · doi:10.1038/s41467-020-20030-5 · Cited by 206
Johnstone, C. N., Smith, Y. E., Cao, Y., Burrows, A. D., Cross, R. S., Ling, X., Redvers, R. P., Doherty, J. P., Eckhardt, B. L., Natoli, A. L., et al. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.017830 · Cited by 214
Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer
Heyn, H., Vidal, E., Ferreira, H. J., Vizoso, M., Sayols, S., Gómez, A., Morán, S., Boqué-Sastre, R., Guil, S., Martínez‐Cardús, A., et al. (2016) · Genome biology · doi:10.1186/s13059-016-0879-2 · Cited by 211
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
Turner, N. C., Neven, P., Loibl, S., & Andre, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32419-9 · Cited by 205
Ai, D., Yao, J., Yang, F., Huo, L., Chen, H., Lü, W., Soto, L. M. S., Jiang, M., Raso, M. G., Wang, S., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-00692-8 · Cited by 205
Epigenome-wide association studies without the need for cell-type composition
Zou, J., Lippert, C., Heckerman, D. E., Aryee, M. J., & Listgarten, J. (2014) · Nature Methods · doi:10.1038/nmeth.2815 · Cited by 204
Sharma, P., Klemp, J. R., Kimler, B. F., Mahnken, J. D., Geier, L. J., Khan, Q. J., Elia, M., Connor, C. S., McGinness, M., Mammen, J., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2980-0 · Cited by 204
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
Piezzo, M., Cocco, S., Caputo, R., Cianniello, D., Gioia, G. D., Lauro, V. D., Fusco, G., Martinelli, C., Nuzzo, F., Pensabene, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186479 · Cited by 212
Hanker, A. B., Pfefferle, A. D., Balko, J. M., Kuba, M. G., Young, C. D., Sánchez, V., Sutton, C. R., Cheng, H., Perou, C. M., Zhao, J. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303204110 · Cited by 203
Paull, E., Carlin, D. E., Niepel, M., Sorger, P. K., Haussler, D. H., & Stuart, J. M. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt471 · Cited by 203
Tumor Cell–Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression
Oudin, M. J., Jonas, O. H., Kosciuk, T., Broye, L. C., Guido, B. C., Wyckoff, J., Riquelme, D. N., Lamar, J. M., Asokan, S. B., Whittaker, C. A., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1183 · Cited by 207
Triple-Negative Breast Cancer and the Potential for Targeted Therapy
Jhan, J.-R., & Andrechek, E. R. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0117 · Cited by 205
Metadata
- Authors
- The Cancer Genome Atlas Network
- Corresponding author
- The Cancer Genome Atlas Network
- Venue
- Nature
- Published
- 2012-09-23
- Volume
- 490
- Issue
- 7418
- Pages
- 61-70
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3465532
- OpenAlex
- W4301159569
- Cited by
- 12,129
- References
- 56
- Citations by year
- 2026: 552 · 2025: 690 · 2024: 761 · 2023: 781 · 2022: 918 · 2021: 1164 · 2020: 1005 · 2019: 961 · 2018: 942 · 2017: 949 · 2016: 979 · 2015: 909 · 2014: 879 · 2013: 590 · 2012: 40
- FWCI
- 256.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Defense
- Breast Cancer Research Foundation (P50CA116201)
- Henry M. Jackson Foundation
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG004028)
- National Cancer Institute (R01CA094143, U24CA143882, U01CA084955, U24CA143840, U24CA143858, U24CA144025, K08CA148912, U24CA143866, U24CA143883, U24CA143845, U24CA143867, U24CA143848, U24CA143799, U24CA143835, P50 CA 58223, P30CA016672, P30CA016058, P50CA058223, P50CA116201, P30CA016086)
- U.S. National Library of Medicine (R01LM009722)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Keywords
- breast cancer, molecular subtypes, tumor heterogeneity, somatic mutations, TP53, PIK3CA, GATA3, MAP3K1, luminal A, HER2-enriched breast cancer, basal-like breast cancer, high-grade serous ovarian cancer, DNA methylation, copy number variation, gene expression signatures, signaling pathways, tumor microenvironment, multi-omics integration
- MeSH terms
- Breast Neoplasms, DNA Mutational Analysis, Female, Humans, Mutation, Ovarian Neoplasms, Receptors, Estrogen, RNA, Messenger, RNA, Neoplasm, Genome, Human, Gene Expression Regulation, Neoplastic, Genes, p53, Retinoblastoma Protein, Genes, erbB-2, Genetic Heterogeneity, DNA Methylation, Genes, BRCA1, Phosphatidylinositol 3-Kinases, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Genomics, MicroRNAs, Protein Array Analysis, Proteomics, MAP Kinase Kinase Kinase 1, GATA3 Transcription Factor, Genes, Neoplasm, DNA Copy Number Variations, Class I Phosphatidylinositol 3-Kinases, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
